Neolaia Bio – Rejuvenating and Extending Human Life

One Target.
Multiple Aging Conditions.
Total Transformation.n.

At Neolaia, we stand at the forefront of biopharmaceutical innovation, pioneering next-generation therapies through precise molecular science that enhances cellular resilience, reduces inflammation, and extends healthspan. Our vision is not merely to treat diseases; we aim to redefine the aging process itself.

EXPLORE OUR APPROACH

Persistent Inflammaging:
Commonly Associated with Aging.

Elevated CD38 reduces NAD+ levels, accelerating mitochondrial dysfunction and inflammation.

Restoring NAD+ by inhibiting CD38 is a promising strategy for treating many age-related conditions.

CD38 Inhibitor:
A Game-Changer in Therapeutics

Our breakthrough catalytic small molecule CD38 inhibitors are engineered to disrupt inflammation-driven cellular aging. By restoring NAD+ levels, we unlock a transformative treatment paradigm for a variety of conditions.

Advanced Immunological Disorders: Halting maladaptive immune responses without compromising safety.
Metabolic Optimization: Tackling diabetes and liver dysfunction head-on.
Precision Weight Management: Empowering individuals with the tools for lasting change.
Enhanced Muscle Performance: Setting new standards for physical excellence.
Sustained Cellular Energy: Elevating vitality at the cellular level.
Entering clinic by end of year.

learn more

Our Development Candidate: NEO-1306

Highly selective, potent molecule.
Convenient once-daily oral dosing.
Excellent safety profile, wide therapeutic window.
Efficacy demonstrated across multiple preclinical models.
Strong patent estate; entering clinic by end of year.

Our Strategy: Target FDA Indications Aligned with Age-Related Conditions

Inflammation, fibrosis, and accelerated aging are key drivers of disease pathology; CD38 plays a critical role.

Lung Function

Muscle Loss/Fatigue

Cognitive Decline

request clinical timeline

Our Frontier Matrix

Patient Need

Our focus is on 3 age-related conditions with strong scientific backing: lung function, muscle loss/fatigue, and cognitive function. By targeting these conditions, we aim to deliver powerful and reversible therapies that minimize safety risks for patients.

Compelling Evidence

CD38 inhibition halts aberrant inflammation, fibrosis, and rejuvenates cells. Restores NAD+ by blocking degradation.

discover our solution

Market Scale

Our solution has the opportunity to touch 30M+ patients with up to $30B global market opportunity.

Expanded Pipeline Information Available

Request a confidential investor briefing for advance insight.

request briefing

Who We Are

Neolaia at a glance

Pre-Clinical Biotech: Founded in November 2023, focused on NAD+ regulation for age-related diseases.
Expert Scientific Leadership: Bringing unparalleled expertise in NAD+ biology and drug development.
Efficient Hybrid Model: Combines virtual operations with collaborations with Contract Research Organizations (CROs) and NC Biolabs facilities.
AI-Enhanced Screening Platform: Utilizes advanced AI technology to identify promising drug candidates with speed and precision.